Annual FCF
-$42.97 M
+$13.70 M+24.18%
30 September 2023
Summary:
Outlook Therapeutics annual free cash flow is currently -$42.97 million, with the most recent change of +$13.70 million (+24.18%) on 30 September 2023. During the last 3 years, it has risen by +$11.28 million (+20.79%). OTLK annual FCF is now -357.79% below its all-time high of -$9.39 million, reached on 30 September 2014.OTLK Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$19.51 M
-$245.00 K-1.27%
30 June 2024
Summary:
Outlook Therapeutics quarterly free cash flow is currently -$19.51 million, with the most recent change of -$245.00 thousand (-1.27%) on 30 June 2024. Over the past year, it has dropped by -$6.77 million (-53.14%). OTLK quarterly FCF is now -35005.90% below its all-time high of $55.90 thousand, reached on 30 September 2017.OTLK Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$64.55 M
-$6.30 M-10.81%
30 June 2024
Summary:
Outlook Therapeutics TTM free cash flow is currently -$64.55 million, with the most recent change of -$6.30 million (-10.81%) on 30 June 2024. Over the past year, it has dropped by -$21.58 million (-50.22%). OTLK TTM FCF is now -1439.07% below its all-time high of -$4.19 million, reached on 31 December 2014.OTLK TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OTLK Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -53.1% | -50.2% |
| 3 y3 years | +20.8% | -117.0% | -19.0% |
| 5 y5 years | -31.3% | -228.3% | -97.3% |
OTLK Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +24.2% | -140.5% | +7.5% | -59.5% | at low |
| 5 y | 5 years | -35.2% | +24.2% | -228.3% | +7.5% | -151.6% | at low |
| alltime | all time | -357.8% | +24.2% | <-9999.0% | +7.5% | -1439.1% | at low |
Outlook Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$19.51 M(+1.3%) | -$64.55 M(+10.8%) |
| Mar 2024 | - | -$19.27 M(+47.8%) | -$58.26 M(+23.7%) |
| Dec 2023 | - | -$13.03 M(+2.3%) | -$47.10 M(+9.6%) |
| Sept 2023 | -$42.97 M(-24.2%) | -$12.74 M(-3.6%) | -$42.97 M(+6.2%) |
| June 2023 | - | -$13.22 M(+62.9%) | -$40.48 M(-16.3%) |
| Mar 2023 | - | -$8.11 M(-8.8%) | -$48.37 M(-11.4%) |
| Dec 2022 | - | -$8.90 M(-13.2%) | -$54.59 M(-3.7%) |
| Sept 2022 | -$56.67 M(+4.5%) | -$10.25 M(-51.4%) | -$56.67 M(+2.3%) |
| June 2022 | - | -$21.10 M(+47.2%) | -$55.41 M(+1.7%) |
| Mar 2022 | - | -$14.33 M(+30.4%) | -$54.51 M(+5.0%) |
| Dec 2021 | - | -$10.99 M(+22.2%) | -$51.92 M(-4.3%) |
| Sept 2021 | -$54.25 M(+70.7%) | -$8.99 M(-55.5%) | -$54.25 M(-5.4%) |
| June 2021 | - | -$20.19 M(+71.9%) | -$57.34 M(+33.0%) |
| Mar 2021 | - | -$11.75 M(-11.8%) | -$43.10 M(+12.1%) |
| Dec 2020 | - | -$13.32 M(+10.3%) | -$38.44 M(+20.9%) |
| Sept 2020 | -$31.79 M(-2.9%) | -$12.08 M(+102.8%) | -$31.79 M(+23.9%) |
| June 2020 | - | -$5.96 M(-15.9%) | -$25.65 M(-14.9%) |
| Mar 2020 | - | -$7.08 M(+6.1%) | -$30.16 M(+2.6%) |
| Dec 2019 | - | -$6.67 M(+12.3%) | -$29.38 M(-10.2%) |
| Sept 2019 | -$32.73 M | -$5.94 M(-43.2%) | -$32.73 M(-10.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | -$10.46 M(+65.7%) | -$36.44 M(+5.1%) |
| Mar 2019 | - | -$6.31 M(-37.0%) | -$34.69 M(-3.9%) |
| Dec 2018 | - | -$10.02 M(+3.7%) | -$36.09 M(+0.8%) |
| Sept 2018 | -$35.82 M(+126.8%) | -$9.66 M(+11.0%) | -$35.82 M(+37.2%) |
| June 2018 | - | -$8.70 M(+12.8%) | -$26.11 M(+13.0%) |
| Mar 2018 | - | -$7.71 M(-20.9%) | -$23.11 M(+18.2%) |
| Dec 2017 | - | -$9.75 M(<-9900.0%) | -$19.55 M(+23.8%) |
| Sept 2017 | -$15.80 M(-66.1%) | $55.90 K(-101.0%) | -$15.80 M(-40.5%) |
| June 2017 | - | -$5.71 M(+37.4%) | -$26.55 M(-28.9%) |
| Mar 2017 | - | -$4.15 M(-30.7%) | -$37.34 M(-7.1%) |
| Dec 2016 | - | -$5.99 M(-44.0%) | -$40.19 M(-13.7%) |
| Sept 2016 | -$46.58 M(+28.4%) | -$10.70 M(-35.1%) | -$46.58 M(-7.2%) |
| June 2016 | - | -$16.49 M(+135.3%) | -$50.19 M(+6.3%) |
| Mar 2016 | - | -$7.01 M(-43.3%) | -$47.22 M(+6.2%) |
| Dec 2015 | - | -$12.38 M(-13.5%) | -$44.46 M(+22.6%) |
| Sept 2015 | -$36.28 M(+286.5%) | -$14.31 M(+5.8%) | -$36.28 M(+65.1%) |
| June 2015 | - | -$13.53 M(+218.0%) | -$21.97 M(+160.1%) |
| Mar 2015 | - | -$4.25 M(+1.4%) | -$8.45 M(+101.4%) |
| Dec 2014 | - | -$4.19 M | -$4.19 M |
| Sept 2014 | -$9.39 M | - | - |
FAQ
- What is Outlook Therapeutics annual free cash flow?
- What is the all time high annual FCF for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly FCF year-on-year change?
- What is Outlook Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Outlook Therapeutics?
- What is Outlook Therapeutics TTM FCF year-on-year change?
What is Outlook Therapeutics annual free cash flow?
The current annual FCF of OTLK is -$42.97 M
What is the all time high annual FCF for Outlook Therapeutics?
Outlook Therapeutics all-time high annual free cash flow is -$9.39 M
What is Outlook Therapeutics quarterly free cash flow?
The current quarterly FCF of OTLK is -$19.51 M
What is the all time high quarterly FCF for Outlook Therapeutics?
Outlook Therapeutics all-time high quarterly free cash flow is $55.90 K
What is Outlook Therapeutics quarterly FCF year-on-year change?
Over the past year, OTLK quarterly free cash flow has changed by -$6.77 M (-53.14%)
What is Outlook Therapeutics TTM free cash flow?
The current TTM FCF of OTLK is -$64.55 M
What is the all time high TTM FCF for Outlook Therapeutics?
Outlook Therapeutics all-time high TTM free cash flow is -$4.19 M
What is Outlook Therapeutics TTM FCF year-on-year change?
Over the past year, OTLK TTM free cash flow has changed by -$21.58 M (-50.22%)